Nature Communications (Oct 2022)
Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma
- Sruthi Ravindranathan,
- Tenzin Passang,
- Jian-Ming Li,
- Shuhua Wang,
- Rohan Dhamsania,
- Michael Brandon Ware,
- Mohammad Y. Zaidi,
- Jingru Zhu,
- Maria Cardenas,
- Yuan Liu,
- Sanjeev Gumber,
- Brian Robinson,
- Anish Sen-Majumdar,
- Hanwen Zhang,
- Shanmuganathan Chandrakasan,
- Haydn Kissick,
- Alan B. Frey,
- Susan N. Thomas,
- Bassel F. El-Rayes,
- Gregory B. Lesinski,
- Edmund K. Waller
Affiliations
- Sruthi Ravindranathan
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Tenzin Passang
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Jian-Ming Li
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Shuhua Wang
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Rohan Dhamsania
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Michael Brandon Ware
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Mohammad Y. Zaidi
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Jingru Zhu
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Maria Cardenas
- Department of Urology, Emory University School of Medicine
- Yuan Liu
- Winship Cancer Institute, Emory University
- Sanjeev Gumber
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine
- Brian Robinson
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine
- Anish Sen-Majumdar
- Cambium Oncology LLC
- Hanwen Zhang
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Shanmuganathan Chandrakasan
- Aflac Cancer and Blood Disorders Center, Emory University
- Haydn Kissick
- Winship Cancer Institute, Emory University
- Alan B. Frey
- Cambium Oncology LLC
- Susan N. Thomas
- Woodruff School of Mechanical Engineering, Georgia Institute of Technology
- Bassel F. El-Rayes
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Gregory B. Lesinski
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- Edmund K. Waller
- Department of Hematology and Medical Oncology, Emory University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-34242-4
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 18
Abstract
Poor antitumor response of pancreatic cancer to immunotherapies is a major barrier to effective disease management. Herein we show that pancreatic cancers overexpress vasoactive intestinal peptide, and pharmacological inhibition of its signaling significantly enhances responsiveness of pancreatic ductal adenocarcinoma to immune checkpoint therapy, thus improving overall survival in mouse models.
